Fusidic acid – topical
Classification: BATC code: D06AX01, D07CA01, D07CC01, S01AA13
Summary
Published controlled studies on differences between men and women on efficacy, safety and pharmacokinetics for topical fusidic acid are lacking.
Additional information
Pharmacokinetics and dosing
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of topical fusidic acid have been found.
Effects
No studies with a clinically relevant sex analysis regarding the effects of topical fusidic acid have been found.
Adverse effects
No studies with a clinically relevant sex analysis regarding adverse effects of topical fusidic acid have been found.
Reproductive health issues
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Other information
A retrospective analysis of patients with eczema or psoriasis on standard dermatological treatment (295 men, 291 women) found that significantly more men than women (79; 63%, 47; 37%) were administered whole-body UV treatment. Also, the results indicated that men had more treatments appointments per individual than women. Women were prescribed more emollients than men [1].
Updated: 2022-09-13
Date of litterature search: 2022-06-29
References
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson